HC Wainwright & Co. maintains Immunocore Holdings at Buy, lowers price target to $80 from $100
HC Wainwright & Co. kept its Buy rating on Immunocore Holdings but reduced its price target to $80 from $100, a 20% cut. This implies a 152.1% upside from the Nov 9 closing price of $31.73, according to the firm.
How this was made

The 30-second read
Why it matters
The downgrade suggests a near-term price correction but does not introduce new catalysts.
Market read
Analyst rating adjustment with modest impact; primarily relevant to existing shareholders.
What to watch
No new clinical data or corporate actions accompany the target change.
Background
HC Wainwright lowered its price target for Immunocore Holdings, citing revised expectations.
Market effects
Minimal impact on biotech sector; price target change reflects analyst view only.
Limited to UK biotech investors.
Low
Counterpoint
The target cut may be overly cautious; upside potential remains if pipeline advances.
Key entities
- AnalystHC Wainwright & Co.
Equity research firm providing the rating and target.